BioLineRx (BLRX) Approved to Evaluate BL-8040 as CML Treatment in Phase 1 ... StreetInsider.com (subscription) BioLineRx (Nasdaq: BLRX) announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a ... |
